In adults, ESA therapy is associated with hypertension, stroke, vascular access thrombosis and overall mortality when higher haemoglobin (Hb) levels (>12.5 g/dL) are targeted [13, 14]. This evidence concerns the gene GSTM1 and Hypertension.